Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
Completed
Novartis Pharmaceuticals
Phase 4
2005-06-01
To allow patients treated with deferasirox in the core study to continue iron chelation
therapy for 2 years or until the drug became locally commercially available. To evaluate the
long-term safety and efficacy of deferasirox by measuring treatment success, change in liver
iron content (LIC) and change in serum ferritin levels. Safety was mainly assessed by
incidence of adverse events (AEs)and clinically significant lab parameters.
Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
Completed
Novartis Pharmaceuticals
Phase 3
2005-10-01
This is an open-label, non-randomized, multi-center trial designed to provide expanded access
of deferasirox to patients with congenital disorders of red blood cells and chronic iron
overload from blood transfusions who cannot adequately be treated with locally approved iron
chelators.
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
Completed
Astellas Pharma Inc
Phase 2
2007-10-01
The purpose of this study is to determine if the addition of the medication, deferasirox, to
standard antifungal therapy for the infection, mucormycosis, is safe and effective
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
Completed
Gilead Sciences
Phase 2
2007-10-01
The purpose of this study is to determine if the addition of the medication, deferasirox, to
standard antifungal therapy for the infection, mucormycosis, is safe and effective
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
Completed
Novartis
Phase 2
2007-10-01
The purpose of this study is to determine if the addition of the medication, deferasirox, to
standard antifungal therapy for the infection, mucormycosis, is safe and effective
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
